Trials / Completed
CompletedNCT04647214
18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)
ARGOS - A Phase IV, Prospective, 18-month Study to Assess the Effectiveness and Safety of Bimatoprost Intracameral Implant (DURYSTA) in US Clinical Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 220 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study to collect effectiveness and safety data after administration of a bimatoprost intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Conditions
Timeline
- Start date
- 2021-03-03
- Primary completion
- 2024-07-12
- Completion
- 2024-07-12
- First posted
- 2020-11-30
- Last updated
- 2025-08-03
Locations
39 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04647214. Inclusion in this directory is not an endorsement.